Detalles de la búsqueda
1.
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Am J Hematol
; 98(5): 730-738, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36869876
2.
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.
Br J Haematol
; 192(6): 978-987, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862447
3.
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.
Oncologist
; 26(7): 597-609, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33870594
4.
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
Ann Hematol
; 100(9): 2279-2292, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33523289
5.
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Ann Hematol
; 99(5): 1049-1061, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32236735
6.
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1671-1682, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29756171
7.
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1747, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29943159
8.
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Ann Hematol
; 94(12): 2033-42, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26420061
9.
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Ann Hematol
; 93(1): 129-39, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23892921
10.
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Am J Hematol
; 89(2): 145-50, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24123068
11.
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Am J Hematol
; 89(8): 803-8, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24757085
12.
Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.
J Clin Med
; 13(2)2024 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38276092
13.
Bone Marrow Iron Stores Are Not Associated with Increased Risk for Invasive Fungal Infections in Patients with Newly Diagnosed Acute Leukemia or Myelodysplastic Syndrome in Transformation: Is There a Relationship?
J Fungi (Basel)
; 9(7)2023 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37504736
14.
Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome.
Sci Rep
; 12(1): 17914, 2022 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36289284
15.
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
In Vivo
; 36(3): 1302-1315, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35478115
16.
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study.
Leukemia
; 35(5): 1418-1427, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33589757
17.
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.
Clin Lymphoma Myeloma Leuk
; 20(2): 114-121, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31884152
18.
Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study.
Infect Dis Ther
; 8(2): 255-268, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30767170
19.
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Cancer Med
; 8(5): 2056-2063, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30897290
20.
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Blood Cancer J
; 8(3): 31, 2018 03 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29523783